Pipeline 2018-04-10T15:49:46+00:00

In the Pipeline…

Cala Medical is developing a portfolio of preclinical projects targeting inflammatory diseases.

Cytoflow5 is the first product in development as an extracorporeal therapy for sepsis.

Our expertise in protein immobilization and formulation is being applied to develop new therapies for diseases that can be targeted through specific control of immune modulators.

Would you like more information?